Tharimmune, Inc. announced on August 20, 2025, positive results from a recent pharmacokinetic (PK) simulation analysis of its lead clinical asset, TH104. TH104 is a buccal film formulation of nalmefene.
The results reinforce the potential of TH104 as a prophylactic countermeasure for military personnel and chemical incident responders. This is specifically for those who may be exposed to high-potency opioids, including weaponized fentanyl and its analogues.
The simulation results highlight potential superiority over existing treatments, suggesting a rapid and predictable delivery profile crucial for emergency countermeasures. This scientific validation supports the strategic advancement of TH104 in this critical national security indication.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.